Stock SNDX SYNDAX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
21.06 USD +2.38% Intraday chart for Syndax Pharmaceuticals, Inc. +1.25% -2.55%
Apr. 08 Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session CI
Mar. 28 Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 238.3 1,048 1,184 1,733 1,833 1,790 - -
Enterprise Value (EV) 1 178.5 754.9 981.6 1,249 1,255 1,499 1,567 1,684
P/E ratio -4.77 x -11.9 x 45.6 x -10.3 x -7.25 x -5.6 x -7.47 x -9.6 x
Yield - - - - - - - -
Capitalization / Revenue 157 x 691 x 8.47 x - - 57 x 14.8 x 7.24 x
EV / Revenue 118 x 498 x 7.03 x - - 47.7 x 12.9 x 6.81 x
EV / EBITDA -3.07 x -10.6 x 36.5 x -8.05 x -5.13 x -4.2 x -5.99 x -9.2 x
EV / FCF -3.53 x -10.6 x 33.8 x -9.34 x -7.82 x -5.82 x -9.08 x -17.7 x
FCF Yield -28.4% -9.44% 2.95% -10.7% -12.8% -17.2% -11% -5.66%
Price to Book 7.54 x 4.22 x - 3.71 x 2.74 x 3.45 x 6.05 x 8.61 x
Nbr of stocks (in thousands) 27,140 47,119 54,074 68,100 84,810 84,980 - -
Reference price 2 8.780 22.24 21.89 25.45 21.61 21.06 21.06 21.06
Announcement Date 3/3/20 3/8/21 3/1/22 2/28/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1.517 1.517 139.7 - - 31.42 121.3 247.3
EBITDA 1 -58.23 -71.33 26.91 -155.1 -244.7 -357.1 -261.8 -183
EBIT 1 -57.54 -71.42 26.22 -151.8 -230 -335.1 -263.8 -203.6
Operating Margin -3,792.95% -4,708.17% 18.77% - - -1,066.7% -217.49% -82.33%
Earnings before Tax (EBT) 1 -56.05 -73.16 24.93 -149.3 -209.4 -325.2 -262.6 -180.4
Net income 1 -56.05 -77.06 24.93 -149.3 -209.4 -314.2 -256.1 -204
Net margin -3,694.59% -5,080.03% 17.84% - - -1,000.04% -211.13% -82.5%
EPS 2 -1.840 -1.870 0.4800 -2.460 -2.980 -3.763 -2.818 -2.193
Free Cash Flow 1 -50.61 -71.26 29 -133.7 -160.6 -257.5 -172.7 -95.33
FCF margin -3,336.32% -4,697.43% 20.76% - - -819.62% -142.36% -38.56%
FCF Conversion (EBITDA) - - 107.79% - - - - -
FCF Conversion (Net income) - - 116.35% - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/3/20 3/8/21 3/1/22 2/28/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 12.38 126.6 - - - - - - - - - - 5.986 25.98
EBITDA 1 - - - - - - - - - -81.36 -75.58 -77.74 -79.98 -
EBIT 1 -20.03 95.75 -36.86 -37.72 -35.14 -42.03 -46.02 -49.68 -56.36 -77.9 -84.14 -88.51 -86.51 -73.4
Operating Margin -161.87% 75.65% - - - - - - - - - - -1,445.18% -282.48%
Earnings before Tax (EBT) 1 -20.64 96.2 -37.17 -37.57 -35.4 -39.19 -41.13 -44.62 -51.15 -72.47 -80.34 -84.41 -80.46 -77.95
Net income 1 -20.64 96.2 -37.17 -37.57 -35.4 -39.19 -41.13 -44.62 -51.15 -72.47 -79.65 -83.8 -81.18 -66.9
Net margin -166.78% 76% - - - - - - - - - - -1,356.1% -257.46%
EPS 2 -0.4000 1.810 -0.6300 -0.6200 -0.5800 -0.6200 -0.5900 -0.6400 -0.7300 -1.000 -0.9738 -1.025 -0.9825 -0.7962
Dividend per Share 2 - - - - - - - - - - - - - -
Announcement Date 11/15/21 3/1/22 5/9/22 8/8/22 11/3/22 2/28/23 5/8/23 8/3/23 11/2/23 2/27/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 59.8 293 202 484 578 291 223 106
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -50.6 -71.3 29 -134 -161 -258 -173 -95.3
ROE (net income / shareholders' equity) -132% -54.3% 7.55% -34.1% -41% -55.6% -98.5% -76.6%
ROA (Net income/ Total Assets) - - - -31.5% -37.7% -55.1% -61.5% -64%
Assets 1 - - - 473.4 555.1 570.4 416.1 318.7
Book Value Per Share 2 1.160 5.270 - 6.860 7.880 6.110 3.480 2.450
Cash Flow per Share 2 - - - - -2.280 -3.080 -0.7600 -
Capex 1 - - 0.13 - - 1.7 1.7 1.7
Capex / Sales - - 0.09% - - 5.41% 1.4% 0.69%
Announcement Date 3/3/20 3/8/21 3/1/22 2/28/23 2/27/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
21.06 USD
Average target price
35.17 USD
Spread / Average Target
+66.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SYNDAX PHARMACEUTICALS, INC. Stock Syndax Pharmaceuticals, Inc.
-2.55% 1.79B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SNDX Stock
  4. Financials Syndax Pharmaceuticals, Inc.